Back to top
more

Clementia Pharmaceuticals Inc. (CMTA)

(Delayed Data from NSDQ)

$26.35 USD

26.35
NA

0.00 (0.00%)

Updated Apr 17, 2019 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

[CMTA]

Reports for Purchase

Showing records 1 - 20 ( 28 total )

Industry: Medical - Biomedical and Genetics

Record: 1

03/08/2019

Company Report

Pages: 4

Dropping coverage Due to Announced Acquisition

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 2

02/26/2019

Company Report

Pages: 3

$1 + $0.3 B Acquisition Agreement Announced

Provider: Bloom Burton & Company

Analyst: MARTIN D

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 3

02/25/2019

Company Report

Pages: 5

D/g to Neutral: French Kiss with a Kick; Ipsen Acquires CMTA for $25/Share +CVR

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 4

12/23/2018

Daily Note

Pages: 29

2019 TOP IDEAS-Healthcare Sector Review Preview.

Provider: Bloom Burton & Company

Price: 75.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 5

12/17/2018

Company Report

Pages: 33

We are initiating research coverage with a BUY rating (Speculative Risk) and a 12-month target price of $18.00

Provider: Bloom Burton & Company

Analyst: MARTIN D

Price: 75.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 6

12/13/2018

Company Report

Pages: 9

De-Risked But Under-loved, We?re Buyers for 2019

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 7

11/08/2018

Company Report

Pages: 7

PVO Stacks Lineup with Ph 3 and pre-NDA in FOP, Ph 2 in MO, and Ph 1 in Dry Eye

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 8

11/08/2018

Daily Note

Pages: 9

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 9

10/24/2018

Company Report

Pages: 7

To Submit Palovarotene NDA for FOP in 2H19 Following Positive FDA Feedback

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 10

10/23/2018

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for CMTA

Provider: ValuEngine, Inc

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 11

09/27/2018

Daily Note

Pages: 7

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 12

09/26/2018

Daily Note

Pages: 4

Updated Ph 2 Part B Data Highlights Importance of Flare-up Protocol in Ph 3

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 13

09/21/2018

Industry Report

Pages: 9

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Industry: Unclassified

Record: 14

08/31/2018

Industry Report

Pages: 9

HEALTHCARE - The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Industry: Unclassified

Record: 15

08/10/2018

Company Report

Pages: 6

2Q18 Financials; Development Programs on Track, Share Weakness Overblown

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Industry: Unclassified

Record: 16

08/10/2018

Company Report

Pages: 5

2Q18 Financials; Development Programs on Track, Share Weakness Overblown

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Industry: Unclassified

Record: 17

08/10/2018

Daily Note

Pages: 10

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Industry: Unclassified

Record: 18

05/23/2018

Company Report

Pages: 5

12mo Part B Data Provides Good Readthrough to MOVE

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Industry: Unclassified

Record: 19

05/10/2018

Daily Note

Pages: 7

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Industry: Unclassified

Record: 20

05/10/2018

Company Report

Pages: 7

Ph 3 Accrual MOVEing Along Nicely, Part B Catalyst Still to Come This Quarter

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party
// eof